

# Information for Connecticut Prescribers of Prescription Drugs

## Mounjaro® (tirzepatide)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

### **Product:**

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST <sup>1</sup>
Mounjaro®	tirzepatide	2.5 mg/0.5 mL	Pen	4	0002-1506-80	\$1069.08
		5 mg/0.5 mL	Pen	4	0002-1495-80	\$1069.08
		7.5 mg/0.5 mL	Pen	4	0002-1484-80	\$1069.08
		10 mg/0.5 mL	Pen	4	0002-1471-80	\$1069.08
		12.5 mg/0.5 mL	Pen	4	0002-1460-80	\$1069.08
		15 mg/0.5 mL	Pen	4	0002-1457-80	\$1069.08

The effectiveness of Mounjaro® (tirzepatide) was not impacted by race, ethnicity, or region for adults with type 2 diabetes mellitus.<sup>2</sup>

See [Prescribing Information](#), including Boxed Warnings.

Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

<sup>1</sup> Source: AnalySource®. Accessed on 01/01/2024. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2024. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

<sup>2</sup> US Mounjaro Prescribing Information.